The Basic Mechanism
Baricitinib works by inhibiting enzymes called Janus kinases, commonly abbreviated JAKs.
JAKs are intracellular signaling proteins. They help transmit messages from cytokine receptors on the surface of cells into the cell nucleus, where changes in gene expression can influence immune activity and inflammation.
Baricitinib primarily inhibits JAK1 and JAK2.
What Are Cytokines?
Cytokines are signaling molecules used by cells of the immune system and other tissues to communicate.
They can regulate:
- Inflammation
- Immune responses
- Cell growth
- Blood-cell development
- Tissue responses to infection
In inflammatory and autoimmune diseases, some cytokine pathways can contribute to persistent or excessive inflammation.
JAK-STAT Signaling
Many cytokine receptors use the JAK-STAT pathway.
The simplified process is:
- A cytokine binds to its receptor.
- Associated JAK enzymes become activated.
- JAKs phosphorylate STAT proteins.
- STAT proteins move into the nucleus.
- Gene expression changes.
- The cell produces a biological response.
Baricitinib interferes with this process by inhibiting JAK activity.
JAK1 and JAK2
Baricitinib has preferential activity against JAK1 and JAK2.
This matters because different cytokines depend on different JAK combinations. By reducing JAK1/JAK2 signaling, baricitinib can influence several immune pathways rather than acting on a single cytokine alone.
Why This Can Help Rheumatoid Arthritis
Rheumatoid arthritis involves chronic immune-mediated inflammation.
Inflammatory signaling can activate immune cells and contribute to persistent inflammation of the synovial tissues surrounding joints.
By reducing relevant cytokine signaling, baricitinib can decrease inflammatory activity and may improve clinical measures of rheumatoid arthritis in appropriate patients.
Why This Can Help Atopic Dermatitis
Atopic dermatitis involves multiple inflammatory pathways.
Patients may experience:
- Itching
- Redness
- Dry skin
- Skin lesions
- Recurrent inflammation
Baricitinib’s JAK pathway inhibition can reduce signaling associated with inflammatory activity.
European authorization recognizes its use for moderate to severe atopic dermatitis in specified patients requiring systemic treatment.
Why This Can Help Alopecia Areata
Alopecia areata is an immune-mediated disease affecting hair follicles.
The immune response can disrupt normal hair growth and produce areas of nonscarring hair loss.
Baricitinib can interfere with inflammatory signaling involved in this immune response. This provides the pharmacologic basis for its use in severe alopecia areata.
Why Mechanism and Safety Are Connected
The immune system is essential for defending the body against infection.
Therefore, reducing immune signaling can have consequences beyond the target disease.
This is one reason serious infection is an important baricitinib safety concern.
Patients receiving baricitinib should report possible infections and follow professional recommendations concerning screening and monitoring.
Effect on Blood Counts
JAK signaling also participates in hematologic processes.
Baricitinib can produce changes in blood-cell counts, which is why laboratory monitoring may be required.
Healthcare professionals may consider treatment interruption or modification when laboratory abnormalities reach clinically significant levels.
Effect on Lipids
Baricitinib treatment can increase lipid parameters such as LDL and HDL cholesterol.
This does not mean every patient will develop cardiovascular disease, but lipid monitoring may be appropriate.
The cardiovascular context should be evaluated as part of overall patient care.
A Targeted Immunomodulator
Baricitinib is sometimes described as a targeted therapy because it acts on a defined intracellular signaling family.
However, it is not completely selective for one disease pathway. JAK signaling is involved in many physiological processes.
Therefore, therapeutic effects and adverse effects are both related to its pharmacologic activity.
Mechanism in Simple Language
A simple way to understand baricitinib is:
Baricitinib reduces certain internal immune-system signals that help drive inflammation.
This can help control diseases in which excessive immune signaling contributes to symptoms.
At the same time, because those signaling pathways also contribute to normal immune function, appropriate medical supervision is important.